Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4.acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
1998
Enhancing Anti-Tumor Effects with DMXAA and 5-HT
Sample size: 6
publication
Evidence: moderate
Author Information
Author(s): CJ Lash, AE Li, M Rutland, BC Baguley, LJ Zwi, WR Wilson
Primary Institution: The University of Auckland
Hypothesis
Can the combination of DMXAA and 5-hydroxytryptamine (5-HT) improve anti-tumor effects in mice?
Conclusion
The combination of DMXAA and 5-HT significantly enhances anti-tumor activity in mice without increasing toxicity.
Supporting Evidence
- DMXAA alone caused dose-dependent inhibition of blood flow.
- Co-administration of 5-HT enhanced necrosis from 8.8% to 38%.
- Combining DMXAA with 5-HT resulted in >99% necrosis at higher doses.
Takeaway
This study shows that mixing two medicines can make them work better against tumors in mice.
Methodology
Mice were treated with DMXAA and/or 5-HT, and tumor blood flow, necrosis, and growth delay were measured.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
C3H/HeN female mice, 22-25 g at the time of treatment.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website